cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kiniksa Pharmaceuticals Ltd
5 own
9 watching
Current Price
$17.61
$-0.25
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,231.06M
52-Week High
52-Week High
22.09000
52-Week Low
52-Week Low
10.64500
Average Volume
Average Volume
0.48M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,231.06M
icon52-Week High22.09000
icon52-Week Low10.64500
iconAverage Volume0.48M
iconDividend Yield--
iconP/E Ratio--
What does the Kiniksa Pharmaceuticals Ltd do?
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More
How much money does Kiniksa Pharmaceuticals Ltd make?
News & Events about Kiniksa Pharmaceuticals Ltd.
Globe Newswire
1 year ago
ARCALYST (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in rheumatoid arthritis; data expected in 1H 2024 Cash reserves expected to fund operations into at least 2025 HAMILTON...
Market News Video
1 year ago
In trading on Tuesday, shares of Kiniksa Pharmaceuticals Ltd (KNSA) crossed below their 200 day moving average of 10.67, changing hands as low as 10.24 per share. Kiniksa Pharmaceuticals Ltd shares are currently trading down about 5.2% on the day...
Globe Newswire
1 year ago
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the closing of the global license agreement ...
Frequently Asked Questions
Frequently Asked Questions
What is Kiniksa Pharmaceuticals Ltd share price today?
plus_minus_icon
Can Indians buy Kiniksa Pharmaceuticals Ltd shares?
plus_minus_icon
How can I buy Kiniksa Pharmaceuticals Ltd shares from India?
plus_minus_icon
Can Fractional shares of Kiniksa Pharmaceuticals Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Kiniksa Pharmaceuticals Ltd stocks?
plus_minus_icon
What is today’s traded volume of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is today’s market capitalisation of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$17.61
$-0.25
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
INHIBRX INC
INHIBRX INC
$34.09
$-0.29 (-0.84 %)
Morphic Holding Inc
Morphic Holding Inc
$27.98
$0.29 (1.05 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.73
$-0.70 (-4.54 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$24.49
$0.47 (1.96 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
INHIBRX INC
INHIBRX INC
$34.09
$-0.29 (-0.84 %)
Morphic Holding Inc
Morphic Holding Inc
$27.98
$0.29 (1.05 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.73
$-0.70 (-4.54 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$24.49
$0.47 (1.96 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00